Novel concepts of statin therapy for cardiovascular risk reduction in hypertension

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Hypertension significantly elevates cardiovascular event risk through mechanisms like endothelial dysfunction, inflammation, and a prothrombotic state.
• Dyslipidemia exacerbates cardiovascular risk synergistically with hypertension.
• HMG CoA reductase inhibitors (statins) are primarily lipid-lowering agents with recognized pleiotropic effects.

Purpose of the Study:

• To review the conventional and novel pleiotropic mechanisms of statins.
• To examine the clinical evidence supporting statin use in hypertensive patients, including those with normal lipid levels.
• To explore statins' potential to counteract hypertension-induced pathological effects.

Main Methods:

• Review of existing literature on statin mechanisms and clinical trials.
• Analysis of studies investigating statins' effects on endothelial function, inflammation, platelet activation, and coagulation.
• Evaluation of clinical data on statin therapy in hypertensive populations.

Main Results:

• Statins exhibit significant pleiotropic effects impacting endothelial function, inflammation, platelet activation, and coagulation.
• These effects address multiple facets of atherogenesis, including plaque rupture and thrombogenesis.
• Growing clinical evidence supports the benefit of statins in hypertensive patients.

Conclusions:

• Statins offer benefits in hypertensive patients beyond lipid reduction due to their pleiotropic actions.
• Statin therapy may prevent pathological effects of hypertension, even in patients with normal lipid profiles.
• Further clinical data supports the consideration of statins for managing cardiovascular risk in hypertension.